N/A N=440 Acupuncture for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Primary: Proportion of Responders at the End of 8-week — 60.6; 36.8 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=17 An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Prostatitis · Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Primary: Global Response Assessment — 2 participants
Phase 2 N=151 Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.
Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Primary: National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) Total Score. — 26.0; 26.8; 27.9; -12.1 Units on a 0 to 43 scale
Phase 3 N=324 Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Primary: Decrease in the NIH-CPSI Total Score by at Least 6 Points — 103; 38 Participants
Phase 3 N=272 Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Prostatitis
Primary: Number of Participants With Decline in Total Score ≥4 for the NIH-CPSI Total Score From Baseline to 12 Weeks — 68; 66 Participants — p=0.99
Phase 2 N=62 An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis
Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Primary: Change From Baseline in Average Daily Pain Score at Week 6 — 5.5; 5.6; -1.4; -1.0 units on a scale
Phase 3 N=139 Efficacy Study of a Standardized Pollen Extract Preparation (Cernilton) to Treat Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP-CPPS)
Chronic Prostatitis · Chronic Pelvic Pain Syndrome
Primary: Symptomatic Improvement in the Pain Domain of National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) — 47; 33 participants — p=<0.05
N/A N=78 Optimizing Psychosocial Treatment of Interstitial Cystitis/Bladder Pain Syndrome
Chronic Interstitial Cystitis · Bladder Pain Syndrome · Cystitis, Interstitial
Primary: Change in the Genitourinary Pain Index (GUPI) 2 Months — 6.6; 4.8 score on a scale
N/A N=69 Novel Web-based, Self-directed Intervention for Chronic Pelvic Pain
Chronic Pelvic Pain · Endometriosis
Primary: Patient Reported Outcomes Measurement Information System (PROMIS) Pain Interference Short Form (SF) 4a Between Groups — 59.2; 63.4 t-scores — p=0.038
N/A N=20 Mindfulness-Based Therapy for Interstitial Cystitis/Bladder Pain Syndrome
Interstitial Cystitis · Mindfulness · Complementary Medicine
Primary: Global Response Assessment (GRA) — 2; 0; 1; 3 participants
N/A N=22 Acupuncture for Female IC/PBSyndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial
Painful Bladder Syndrome · Interstitial Cystitis
Primary: Efficacy of Acupuncture to Reduce Pain in Women With Interstitial Cystitis/Painful Bladder Syndrome — -2.08; -2.91 score on a scale
Phase 4 N=72 Interstitial Cystitis: Examination of the Central Autonomic Network
Interstitial Cystitis/Painful Bladder Syndrome · Myofascial Pelvic Pain
Primary: Total Score on Genitourinary Pain Index (GUPI) Scale — 24.4; 22.2; 2.35; 29.25 score on a scale
Phase 3 N=242 An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis
Prostatitis
Primary: Clinical Success — 46; 48; 52 Participants
N/A N=16 Pilot Study of Percutaneous Posterior Tibial Nerve Stimulation for the Treatment of IC/PBS
Interstitial Cystitis · Painful Bladder Syndrome
Primary: Primary Outcome Measure: Percentage of Subjects Improved Global Response Assessment Scale — 4; 3 Participants — p=0.317
N/A N=10 PEMF Therapy to Treat Interstitial Cystitis/Bladder Pain Syndrome
Interstitial Cystitis · Chronic Interstitial Cystitis · Bladder Pain Syndrome
Primary: Pelvic Pain, as Measured by the Numeric Rating Scale (NRS) — 6.70 score on a scale
N/A N=40 PTNS Versus Sham Efficacy in Treatment of BPS
Interstitial Cystitis Bladder Pain Syndromes
Primary: Count of Participants With Patient Global Impression of Improvement (PG-I) Score = 1 or 2 — 2; 4 Participants
N/A N=208 Conservative Treatment of Postprostatectomy Incontinence
Urinary Incontinence
Primary: Percent Change in Incontinence Episodes on Bladder Diary — 55; 51; 24 % change in episodes per week — p=.001
Phase 3 N=271 Efficacy of Amitriptyline for Painful Bladder Syndrome (PBS)
Bladder Diseases · Interstitial Cystitis
Primary: Global Response Assessment (GRA) — 74; 61; 61; 75 Participants
Phase 3 N=420 Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Benign Prostatic Hypertrophy
Primary: International Prostate Symptom Score (IPSS) — -6.2; -5.1; -5.7 Units on a scale — p=0.371
N/A N=16 Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)
Interstitial Cystitis · Pelvic Pain
Primary: Change in Symptom Severity at 4 and 8 Weeks Post-Treatment as Measured by the Total O'Leary-Sant IC Symptom and Problem Index (ICSI/ICPI) Score — -4; -4 units on a scale
Phase 2 N=96 Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB
Lower Urinary Tract Symptoms
Primary: Lactobacillus Safety — .594 Adverse Events — p==0.219
N/A N=97 Mindfulness and Yoga for Pain With Interstitial Cystitis Evaluation
Interstitial Cystitis
Primary: Number of Participants Designated as "Treatment Responders" Based on Global Response Assessment (GRA) — 31; 10 Participants
Phase 4 N=510 Antibiotic Prophylaxis for Transrectal Prostate Biopsy
Infection
Primary: Number of Participants With Post-biopsy Infection. — 6; 3 participants — p=<0.05
Phase 2 N=7 Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB
Lower Urinary Tract Symptoms
Primary: Lactobacillus Safety — .286 Adverse Events — p==0.351
Phase 2 N=69 Efficacy and Safety of AQX-1125 in IC/BPS
Interstitial Cystitis · Bladder Pain Syndrome
Primary: Change From Baseline in the Average Daily Bladder Pain Score (e-Diary) — 6.4; 6.7; -2.4; -1.4 units on a scale — p=0.061
Phase 3 N=42 Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis
Cystitis, Interstitial
Primary: IC/BPS Symptoms Change With Overall Global Response Assessment (GRA) — 2; 1 Participants
N/A N=69 Efficacy of Pain Neuroscience Education in Genito-Pelvic Pain/Penetration Disorder. A Randomized Controlled Trial.
Pain · Dysfunction Sexual
Primary: Visual Analogue Scale — 5.3; 5.8; 5.1; 3.8 score on a scale
N/A N=40 Addition of Pudendal Blocks to Pelvic Floor Physical Therapy for the Treatment of Pelvic Floor Tension Myalgia
Pelvic Floor Muscle Spasm
Primary: Visual Analog Pain Score After 6 Weekly Injections — 3.33; 2.99 Visual Analog Pain Score
Phase 2 N=100 An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia (BPH)
Primary: Change of IPSS at the 6th Week Compared With Baseline(Intention to Treat) — 7.26; 2.34 units on a scale — p=< 0.01
Phase 4 N=395 Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1
Bladder Outlet Obstruction
Primary: The Global Response Assessment (GRA) After the Treatment Day — 89; 218; 27; 61 participants